IPSC Century Therapeutics, Inc. Insider Trading

CSO Chad Cowan buys 58,060 shares of IPSC at $0.85; holdings now 1,045,087 shares amid +194.8% YoY revenue growth but ongoing losses.

Chad Cowan, Chief Scientific Officer, purchased 58,060 shares at $0.85 on 2025-12-22, increasing holdings to 1,045,087 shares post-transaction. The purchase occurred when IPSC's stock was trading 9.9% below its 52-week high of $1.11 and near recent price momentum (+83.4% over 30 days, +100.8% over 90 days). Century Therapeutics is growing top-line revenue substantially at +194.8% annual growth with a recent quarter revenue of $109,164,000, but remains unprofitable with full-year net income of $-34,422,000 and a market cap of $87,307,091—a company where cash burn and growth dynamics are critical to valuation. The insider's accumulation of 58,060 shares (5.9% increase in holdings) during a period of strong recovery from 52-week lows may reflect assessment of company fundamentals, though investors should scrutinize whether profitability timelines and burn rate justify current valuations.

Century Therapeutics CEO Pfeiffenberger buys 52,000 shares at $0.58 amid 30-day 31.3% rally from near 52-week lows

Pfeiffenberger purchased 52,000 shares at $0.58 on 2025-12-12, increasing his holdings to 3.32M shares. The purchase occurred during a period of significant positive price momentum: the stock has risen 31.3% over 30 days and 26.0% over 90 days, though it remains -54.1% from its 52-week high of $1.35 and trades at a $0.62 current price. The company is unprofitable with net income of $-34.4M against quarterly revenue of $109.2M, but has demonstrated strong topline growth of 194.8% year-over-year. The insider's own track record is minimal—one prior buy across all tickers with outcome not yet measurable—providing limited context for interpreting conviction. This buy represents a 1.6% increase to holdings and follows another Century Therapeutics purchase on 2025-11-19, suggesting sustained accumulation during a recovery phase off depressed valuations.

CEO Pfeiffenberger buys 35,000 IPSC shares at $0.50; stock down 71.5% from 52-week high despite 194.8% revenue growth

Brent Pfeiffenberger, President and CEO of Century Therapeutics, purchased 35,000 shares at $0.50 on 2025-11-19, expanding his holdings to 3,271,453 shares. The transaction occurs in a challenging backdrop: the stock trades at $0.49 (current price), off 71.5% from the 52-week high of $1.72 and down 13.3% over the prior 30 days. Despite material top-line expansion (annual revenue growth of 194.8%), the company remains unprofitable with a $-34.4M net loss in the most recent period, and the market cap of $42.8M now represents a significant discount to the company's quarterly revenue of $109.2M. A CEO equity purchase at a depressed valuation amid revenue acceleration may warrant attention to whether management sees near-term catalysts or turnaround mechanics, but the absence of a broader insider transaction pattern limits what can be concluded from this single trade.

Director Quimi Daphne purchases 5,000 shares of IPSC at $1.53 as stock trades -70.1% from 52-week high

Quimi Daphne, a Director, purchased 5,000 shares at $1.53 on 2024-09-12, establishing an initial position in Century Therapeutics. The company is unprofitable with net income of $-31.2M in its most recent full year, while annual revenue growth contracted by -57.0%, reflecting significant operational challenges. The stock is currently priced at $1.59, down -70.1% from its 52-week high of $5.32, suggesting a distressed valuation environment. Across Quimi Daphne's cross-ticker trading history, prior purchases have averaged +5.2% returns over 90 days with a 100% win rate, though this specific purchase at depressed levels and the company's deteriorating financial trajectory represent distinct risk factors to monitor independently of prior outcomes.